The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status

被引：102

作者：

Andre, Thierry ^{[1
]}

Iveson, Timothy ^{[2
]}

Labianca, Roberto ^{[3
]}

Meyerhardt, Jeffrey A. ^{[4
]}

Souglakos, Ioannis ^{[5
]}

Yoshino, Takayuki ^{[6
]}

Paul, James ^{[7
]}

Sobrero, Alberto

Taieb, Julien ^{[8
]}

Shields, Anthony F. ^{[9
]}

Ohtsu, Atsushi ^{[7
]}

Grothey, Axel ^{[10
]}

Sargent, Daniel J. ^{[10
]}

机构：

[1] UPMC, Saint Antoine Hosp, Dept Med Oncol, Paris, France

[2] Univ Hosp Southampton NHS Fdn Trust, Southampton, England

[3] Ospedali Riuniti Bergamo, Oncol Unit, Bergamo, Italy

[4] Dana Farber Canc Inst, Harvard Med Sch, Boston, MA 02115 USA

[5] Univ Hosp Herakl, Dept Med Oncol, Iraklion, Greece

[6] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Chiba, Japan

[7] Beatson West Scotland Canc Ctr, CTU, Glasgow, Lanark, Scotland

[8] Univ Paris 05, European Hosp Georges Pompidou, Digest Oncol Dept, Paris, France

[9] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI 48202 USA

[10] Mayo Clin, Rochester, MN 55902 USA

来源：

CURRENT COLORECTAL CANCER REPORTS | 2013年 / 9卷 / 03期

基金：

英国医学研究理事会;

关键词：

Colon cancer; Colonic neoplasms; Adjuvants pharmaceutic; Stage III; Chemotherapy; Fluoropyrimidines; 5-Fluorouracil; Leucovorin; Oxaliplatin; Capecitabine; Phase III; Duration of therapy; Neuropathy; International collaboration;

D O I：

10.1007/s11888-013-0181-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration was established to prospectively combine and analyze data from several randomized trials conducted around the world to answer whether a three-month course of oxaliplatin-based adjuvant therapy (FOLFOX4/ modified FOLFOX6 or XELOX) is non-inferior to the current standard six-month treatment for patients with stage III colon cancer, with a primary endpoint of three years disease-free survival. The IDEA steering committee comprises two members from each group coordinating an individual trial and two members from a secretariat who coordinate combining of the data and management of the joint analysis. Members of the IDEA agreed to combine the data from their individual trials to enable definitive analysis consisting of at least 10,500 patients. With accrual of 8,797 patients at the end of February 2013, the IDEA is on track to achieve its accrual objective of at least 10,500 patients by the end of 2013.

引用

页码：261 / 269

页数：9

共 18 条

[1] Patterns of Adjuvant Chemotherapy Use in a Population-Based Cohort of Patients With Resected Stage II or III Colon Cancer [J].

Abrams, Thomas A. ;

Brightly, Rick ;

Mao, Jianbin ;

Kirkner, Gregory ;

Meyerhardt, Jeffrey A. ;

Schrag, Deborah ;

Fuchs, Charles S. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) :3255-3262

[2] Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer A Randomized Trial [J].

Alberts, Steven R. ;

Sargent, Daniel J. ;

Nair, Suresh ;

Mahoney, Michelle R. ;

Mooney, Margaret ;

Thibodeau, Stephen N. ;

Smyrk, Thomas C. ;

Sinicrope, Frank A. ;

Chan, Emily ;

Gill, Sharlene ;

Kahlenberg, Morton S. ;

Shields, Anthony F. ;

Quesenberry, James T. ;

Webb, Thomas A. ;

Farr, Gist H., Jr. ;

Pockaj, Barbara A. ;

Grothey, Axel ;

Goldberg, Richard M. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (13) :1383-1393

[3] Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 [J].

Allegra, Carmen J. ;

Yothers, Greg ;

O'Connell, Michael J. ;

Sharif, Saima ;

Petrelli, Nicholas J. ;

Colangelo, Linda H. ;

Atkins, James N. ;

Seay, Thomas E. ;

Fehrenbacher, Louis ;

Goldberg, Richard M. ;

O'Reilly, Seamus ;

Chu, Luis ;

Azar, Catherine A. ;

Lopa, Samia ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) :11-16

[4] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].

Andre, T ;

Boni, C ;

Mounedji-Boudiaf, L ;

Navarro, M ;

Tabernero, J ;

Hickish, T ;

Topham, C ;

Zaninelli, M ;

Clingan, P ;

Bridgewater, J ;

Tabah-Fisch, I ;

de Gramont, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351

[5] Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer:: Results of a randomized trial [J].

André, T ;

Colin, P ;

Louvet, C ;

Gamelin, E ;

Bouche, O ;

Achille, E ;

Colbert, N ;

Boaziz, C ;

Piedbois, P ;

Tubiana-Mathieu, N ;

Boutan-Laroze, A ;

Flesch, M ;

Buyse, M ;

de Gramont, A .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2896-2903

[6] Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients:: Final results of GERCOR c96.1 [J].

Andre, Thierry ;

Quinaux, Emmanuel ;

Louvet, Christophe ;

Colin, Philippe ;

Gamelin, Erik ;

Bouche, Olivier ;

Achille, Emmanuel ;

Piedbois, Pascal ;

Tubiana-Mathieu, Nicole ;

Boutan-Laroze, Arnaud ;

Flesch, Michel ;

Lledo, Gerard ;

Raoul, Yves ;

Debrix, Isabelle ;

Buyse, Marc ;

de Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (24) :3732-3738

[7] Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].

Andre, Thierry ;

Boni, Corrado ;

Navarro, Matilde ;

Tabernero, Josep ;

Hickish, Tamas ;

Topham, Clare ;

Bonetti, Andrea ;

Clingan, Philip ;

Bridgewater, John ;

Rivera, Fernando ;

de Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116

[8] A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer [J].

Chau, I ;

Norman, AR ;

Cunningham, D ;

Tait, D ;

Ross, PJ ;

Iveson, T ;

Hill, M ;

Hickish, T ;

Lofts, F ;

Jodrell, D ;

Webb, A ;

Oates, JR .

ANNALS OF ONCOLOGY, 2005, 16 (04) :549-557

[9] Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial [J].

de Gramont, Aimery ;

Van Cutsem, Eric ;

Schmoll, Hans-Joachim ;

Tabernero, Josep ;

Clarke, Stephen ;

Moore, Malcolm J. ;

Cunningham, David ;

Cartwright, Thomas H. ;

Hecht, J. Randolph ;

Rivera, Fernando ;

Im, Seock-Ah ;

Bodoky, Gyoergy ;

Salazar, Ramon ;

Maindrault-Goebel, Frederique ;

Shacham-Shmueli, Einat ;

Bajetta, Emilio ;

Makrutzki, Martina ;

Shang, Aijing ;

Andre, Thierry ;

Hoff, Paulo M. .

LANCET ONCOLOGY, 2012, 13 (12) :1225-1233

[10] Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer:: A randomized study of the European organization for research and treatment of cancer genitourinary tract cancer cooperative group and the medical research council [J].

de Wit, R ;

Roberts, JT ;

Wilkinson, PM ;

de Mulder, PHM ;

Mead, GM ;

Fosså, SD ;

Cook, P ;

de Prijck, L ;

Stenning, S ;

Collette, L .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1629-1640

← 1 2 →